Figure 2. Computed tomography (CT) scans of a NSCLC patient (case #5, Table 2) with two sensitive EGFR mutations (L858R in exon 21 and G873E in exon 21) and a PIK3CA mutation (E542K in exon 9).

a) CT at baseline, and b) CT taken 5 months after treatment initiation with erlotinib/cetuximab/bevacizumab demonstrating a PR (-55%). Duration of response = 9+ months. Patient had received prior erlotinib for 14.3 months.